Mahmud Shabnur, Alam Safaet, Emon Nazim Uddin, Boby Umme Habiba, Ahmed Firoj, Monjur-Al-Hossain A S M, Tahamina Afroza, Rudra Sajib, Ajrin Marzina
School of Health and Life Sciences, Department of Pharmaceutical Sciences, North South University, Dhaka 1229, Bangladesh.
Pharmaceutical Sciences Research Division, BCSIR Laboratories, Dhaka, Bangladesh Council of Scientific and Industrial Research (BCSIR), Dr. Qudrat-I-Khuda Road, Dhanmondi, Dhaka 1205, Bangladesh.
Saudi Pharm J. 2022 Sep;30(9):1360-1371. doi: 10.1016/j.jsps.2022.06.017. Epub 2022 Jun 22.
This study intends to evaluate the development, importance, pre-clinical and clinical study evaluation of stem cell therapy for the treatment of cardiovascular disease. Cardiovascular disease is one of the main causes of fatality in the whole world. Though there are great progressions in the pharmacological and other interventional treatment options, heart diseases remain a common disorder that causes long-term warnings. Recent accession promotes the symptoms and slows down the adverse effects regarding cardiac remodelling. But they cannot locate the problems of immutable loss of cardiac tissues. In this case, stem cell treatment holds a promising challenge. Stem cells are the cells that are capable of differentiating into many cells according to their needs. So, it is assumed that these cells can distinguish into many cells and if these cells can be individualized into cardiac cells then they can be used to replace the damaged tissues of the heart. There is some abridgment in this therapy, none the less stem cell therapy remains a hopeful destination in the treatment of heart disease.
本研究旨在评估用于治疗心血管疾病的干细胞疗法的发展、重要性、临床前及临床研究评估。心血管疾病是全球主要死因之一。尽管在药物治疗和其他介入治疗方法方面取得了巨大进展,但心脏病仍然是一种常见疾病,会引发长期警报。近期的研究进展改善了症状并减缓了心脏重塑的不良影响。但它们无法解决心脏组织不可逆转损失的问题。在这种情况下,干细胞治疗面临着一项充满希望的挑战。干细胞是能够根据自身需求分化为多种细胞的细胞。因此,可以推测这些细胞能够分化为多种细胞,如果这些细胞能够分化为心脏细胞,那么它们就可用于替换受损的心脏组织。这种疗法存在一些不足,尽管如此,干细胞疗法在心脏病治疗中仍是一个充满希望的方向。